Novartis Q1 2026 Results: Strong Growth in Priority Brands Amid Generic Erosion
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Tag: Quarterly Results
Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion
Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.
Abbott Announces Q1 2026 Results Amidst Strategic Abbott Acquisition of Exact Sciences
Abbott (NYSE: ABT) has released its first-quarter 2026 financial results, showcasing strong organic growth and the strategic integration of Exact Sciences into its world-leading diagnostics portfolio.
Merck Group Q3 2025: Strong Organic Growth Across All Sectors
Merck delivered solid Q3 2025 results, achieving 5.2% organic growth that successfully offset significant currency headwinds. This resilience was seen across all three business sectors, driven by strong demand for Process Solutions in Life Science, the new Rare Diseases franchise in Healthcare, and AI-driven demand for Semiconductor Solutions.
AstraZeneca Posts Strong Q3 Results, Citing 11% Revenue Growth in 2025 Driven by Oncology and Pipeline Success
AstraZeneca has reported strong Q3 2025 results, driven by an 11% increase in Total Revenue for the first nine months of the year. The company’s success is fueled by a 16% growth in Oncology and significant advancements in its R&D pipeline, which has seen 16 positive Phase III trials year-to-date. AstraZeneca also reiterated its full-year guidance and highlighted strategic investments, including a new $4.5 billion manufacturing facility in the US.
Amgen Q3 Revenue Jumps 12% to $9.6 Billion, Driven by Strong Volume Growth
Amgen announced strong third-quarter 2025 financial results, with total revenues increasing 12% to $9.6 billion, driven by a 14% surge in product sales volume. While GAAP EPS rose 14% to $5.93, non-GAAP EPS saw a modest 1% increase due to a 31% jump in R&D spending to advance its late-stage pipeline, including the obesity drug MariTide.
AbbVie Q3 Revenue Jumps 9.1% on Immunology Strength; Company Lifts 2025 EPS Guidance
AbbVie announced third-quarter 2025 net revenues of $15.776 billion, a 9.1% increase, fueled by strong growth from its immunology drugs Skyrizi and Rinvoq. GAAP diluted EPS was $0.10, impacted by IPR&D expenses, while adjusted diluted EPS was $1.86. Following the strong quarter, AbbVie raised its full-year 2025 adjusted diluted EPS guidance to $10.61 – $10.65.
Gilead Announces 2025 Q3 Results; Lifts EPS Guidance as Strong HIV Sales and Other Revenue Drive
Gilead Sciences (GILD) reported strong Q3 2025 financial results, with total revenues of $7.8 billion and non-GAAP diluted EPS jumping 22% to $2.47. The performance was driven by a 4% rise in its core business (excluding Veklury), led by its HIV franchise and $3.7 billion in Biktarvy sales. Despite a decline in Veklury and Cell Therapy revenue, the company raised its full-year 2025 diluted EPS guidance.
Eli Lilly’s Q3 2025 Results Soar: Revenue Jumps 54% on Blockbuster Demand for GLP-1 Therapies; Full-Year Guidance Raised
Eli Lilly reported blockbuster Q3 2025 earnings, with revenue hitting $17.6 billion on 54% year-over-year growth. The financial success was overwhelmingly driven by its incretin portfolio, particularly the high-demand GLP-1 drugs Mounjaro and Zepbound, which saw their sales soar. Following the strong performance and R&D momentum including positive Phase 3 data for the oral obesity drug orforglipron Lilly significantly raised its full-year 2025 revenue and EPS guidance.
IQVIA Posts Strong Q3 2025 Results, Lifts Free Cash Flow
For the third quarter that concluded on September 30, 2025, IQVIA Holdings Inc. (NYSE: IQV) posted solid financial results. The company’s profit and revenue were [Read More…]
